ArticleMolecular diversity2026
TaLiRAGen: target-aware ligand generation via retrieval-augmented large language models.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PharmaGNN: a model for odor prediction based on graph neural networks.Journal of the science of food and agriculture · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generating ligands with high binding affinity for specific protein targets is a fundamental challenge in structure-based drug design. While generative models like VAEs and diffusion models show promise, they suffer from two key limitations: heavy dependence on target-specific training data and underutilization of vast biochemical knowledge. To overcome these issues, we propose TaLiRAGen, a no-training framework for target-aware ligand generation. Our method leverages general chemical knowledge embedded in Large Language Models (LLMs) through Retrieval-Augmented Generation (RAG), eliminating the need for target-specific model training. TaLiRAGen retrieves protein-ligand contexts from diverse repositories, integrates them through Chain-of-Thought (CoT)-augmented multi-turn prompting, and refines molecules via docking feedback. To enhance LLM’s ability in evaluating generated ligands, a unified evaluation metric is developed using evidence-theoretic normalization, jointly assessing binding affinity and drug-like properties. Critically, TaLiRAGen enables flexible, prompt-driven customization, successfully generating ligands that meet diverse structural requirements (e.g., LogP, ring count) for therapeutic targets. The codes and models are available in the supplement materials.
Indexed as
Identifiers
41723766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.